Cargando…

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma

INTRODUCTION: For patients with diffuse large B‐cell lymphoma (DLBCL), standard‐care is rituximab administered with CHOP or CHOP‐like chemotherapy (R‐CHOP). However, the effectiveness and safety of R‐CHOP among DLBCL patients with human immunodeficiency virus (HIV) infection is less clear, as HIV+ p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Habbous, Steven, Guo, Helen, Beca, Jaclyn, Dai, Wei Fang, Isaranuwatchai, Wanrudee, Cheung, Matthew, Chan, Kelvin K. W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541135/ https://www.ncbi.nlm.nih.gov/pubmed/32794362 http://dx.doi.org/10.1002/cam4.3362

Ejemplares similares

Economic evaluation of smoking cessation in Ontario's regional cancer programs
por: Djalalov, Sandjar, et al.
Publicado: (2018)

Are population‐based patient‐reported outcomes associated with overall survival in patients with advanced pancreatic cancer?
por: Dai, Wei Fang, et al.
Publicado: (2019)

Recent survival trends in diffuse large B‐cell lymphoma––Have we made any progress beyond rituximab?
por: Epperla, Narendranath, et al.
Publicado: (2020)

Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer
por: Arciero, Vanessa, et al.
Publicado: (2022)

A prognostic model, including the EBV status of tumor cells, for primary gastric diffuse large B‐cell lymphoma in the rituximab era
por: Ishikawa, Eri, et al.
Publicado: (2018)

Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy
por: Suzuki, Tomotaka, et al.
Publicado: (2021)

Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis
por: Chan, Kelvin K. W., et al.
Publicado: (2019)

Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis
por: Khor, Sara, et al.
Publicado: (2014)

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada
por: Dai, Wei Fang, et al.
Publicado: (2020)

Role of radiation therapy in primary breast diffuse large B‐cell lymphoma in the Rituximab era: a SEER database analysis
por: Liu, Pan‐pan, et al.
Publicado: (2018)

Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces
por: Pataky, Reka E., et al.
Publicado: (2021)

Impact of smoking on health system costs among cancer patients in a retrospective cohort study in Ontario, Canada
por: Isaranuwatchai, Wanrudee, et al.
Publicado: (2019)

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
por: Chan, Kelvin, et al.
Publicado: (2020)

Prediction of survival of diffuse large B‐cell lymphoma patients via the expression of three inflammatory genes
por: Zhao, Shuangtao, et al.
Publicado: (2016)

Cost‐effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person‐level data in a Canadian setting
por: Thein, Hla‐Hla, et al.
Publicado: (2017)

Associations between race and survival in pediatric patients with diffuse large B‐cell lymphoma
por: Khullar, Karishma, et al.
Publicado: (2021)

Maintenance rituximab in Veterans with follicular lymphoma
por: Halwani, Ahmad S., et al.
Publicado: (2020)

Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients
por: Hu, Maogui, et al.
Publicado: (2021)

OSdlbcl: An online consensus survival analysis web server based on gene expression profiles of diffuse large B‐cell lymphoma
por: Dong, Huan, et al.
Publicado: (2020)

Surgery shows survival benefit in patients with primary intestinal diffuse large B‐cell lymphoma: A population‐based study
por: Wang, Moran, et al.
Publicado: (2021)

The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer
por: Raphael, Michael J., et al.
Publicado: (2021)

Primary breast diffuse large B-cell lymphoma in the era of rituximab
por: Zhang, Na, et al.
Publicado: (2016)

Rituximab maintenance therapy of follicular lymphoma in clinical practice
por: Dührsen, Ulrich, et al.
Publicado: (2018)

Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada
por: Habbous, Steven, et al.
Publicado: (2022)

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
por: Zhang, Peng‐Fei, et al.
Publicado: (2020)

MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma
por: Kwanhian, Wiyada, et al.
Publicado: (2012)

Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful
por: Shah, Hina J., et al.
Publicado: (2017)

Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
por: Yelvington, Bradley J.
Publicado: (2018)

Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B‐cell lymphoma
por: Li, Xiaoqian, et al.
Publicado: (2019)

β-Elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway
por: Hu, Tonglin, et al.
Publicado: (2020)

Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization
por: Lu, Brandon, et al.
Publicado: (2023)

Patient Survival With and Without Radiation Therapy for Early-Stage Diffuse Large B-Cell Lymphoma in the Era of PET and Rituximab
por: McLaughlin, Christopher, et al.
Publicado: (2022)

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
por: Vacirca, Jeffrey L., et al.
Publicado: (2013)

The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era
por: Kobayashi, T, et al.
Publicado: (2016)

Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma
por: Hu, Xin, et al.
Publicado: (2017)

Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
por: Papageorgiou, Sotirios G., et al.
Publicado: (2022)

The impact of structural factors on diagnostic delay in diffuse large B‐cell lymphoma
por: Zurko, Joanna C., et al.
Publicado: (2019)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
por: Terada, Yoshiki, et al.
Publicado: (2009)

The average relative dose intensity of R‐CHOP is an independent factor determining favorable overall survival in diffuse large B‐cell lymphoma patients
por: Długosz‐Danecka, Monika, et al.
Publicado: (2019)

Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real‐world analysis from Taiwan Cancer Registry Database
por: Huang, Huai‐Hsuan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ul0phk9vttb0tj5ivouvrrn8j3